Natco Pharma announced that it has launched the first licensed generic version of ledipasvir + sofosbuvir combination of Nepal, under its brand name Hepcinat LP.
Ledipasvir + Sofosbuvir is a two drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences Inc. under its brand HARVONI. It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. NATCO priced generic medicine, Hepcinat LP, at an MRP of INR 25,000 for a bottle of 28 tablets in Nepal.
Natco Pharma today said it has launched generic Hepcinat LP, which is in the treatment of chronic hepatitis Cinfection in adults, in Nepal.
NATCO priced its generic medicine, Hepcinat LP, at Rs 25,000 for a bottle of 28 tablets in Nepal, the company said in a filing to the BSE.
Hepcinat LP is generic version of Ledipasvir and Sofosbuvir combination and is used in the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Natco had signed a non-exclusive licensing agreement with Gilead Sciences earlier in 2015, to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of HARVONI, in India and other 100 developing countries.
Article Source ;